enVVeno Medical Corp is a medical device company focused on the advancement of bioprosthetic (tissue-based) solutions to improve the standard of care for the treatment of venous disease. The company first developed the VenoValve, which was a surgical replacement venous valve. It is focused on its next-generation, non-surgical venous valve product, called the enVVe System which consists of the enVVe Valve, enVVe Delivery System, enVVe Nose Cone, the enVVe Delivery System Accessories, and the enVVe Crimping System. The enVVe System is designed to treat severe deep chronic venous insufficiency through a minimally invasive, catheter-based approach. It operates in a single segment, Medical Device development, located in a single geographic location, the United States.
Last trade$0.00
Day change$0.00 (0.00%)
Day range$5.63 – $6.10
Volume10,462
Market cap$4M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$4.13M
Price / earnings
—
Price / book
0.24×
Price / sales
—
EV / sales
—
EV / EBITDA
-0.09×
Profitability
Earnings per share
-$22.38
Return on assets
-79.8%
Return on equity
-92.02%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
7.35×
Quick ratio
7.35×
Cash ratio
1×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$13.41M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for NVNO, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$0
$0
$0
$0
$0
$0
$0
$0
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$0
$0
$0
$0
$0
$0
$0
$0
Selling, general and administrative
$1.66M
$1.72M
$1.95M
$2.07M
$2.3M
$4.16M
$2.4M
$3.19M
Research and development
$2.88M
$2.08M
$2.11M
$1.95M
$2.59M
$2.89M
$2.56M
$3.51M
Total operating expenses
$4.53M
$3.8M
$4.06M
$4.01M
$4.88M
$7.05M
$4.95M
$6.7M
Operating income
-$4.53M
-$3.8M
-$4.06M
-$4.01M
-$4.88M
-$7.05M
-$4.95M
-$6.7M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$4.37M
-$3.6M
-$3.85M
-$3.74M
-$4.54M
-$6.69M
-$4.5M
-$6.23M
Income taxes
$0
$0
$0
$0
$0
$0
$0
$0
Net income
-$4.37M
-$3.6M
-$3.85M
-$3.74M
-$4.54M
-$6.69M
-$4.5M
-$6.23M
Net income attributable to common shareholders
-$4.37M
-$3.6M
-$3.85M
-$3.74M
-$4.54M
-$6.69M
-$4.5M
-$6.23M
EBITDA
-$4.52M
-$3.86M
-$4.03M
-$3.98M
-$4.85M
-$7.02M
-$4.91M
-$6.66M
Basic earnings per share
-$6.29
-$5.37
-$5.89
-$6.04
-$7.89
-$11.52
-$7.75
-$10.68
Diluted earnings per share
-$6.29
-$5.37
-$5.89
-$6.04
-$7.89
-$11.52
-$7.75
-$10.68
Recent news
Company coverage with links to the original publishers.
The chronic venous insufficiency market is projected to grow from $2.1 billion in 2024 to a larger market by 2034, driven by emerging therapies, medical devices, and increasing prevalence of the condition in aging populations.